Abstract

Osteosarcoma is one of the most common primary tumours of the bone, with a 5-year survival rate of less than 20% after the development of metastases. Osteosarcoma is highly predisposed in Paget's disease of the bone, and both have common characteristic skeletal features due to rapid bone remodelling. Osteosarcoma prognosis is location dependent, which further emphasizes the likely contribution of the bone microenvironment in its pathogenesis. Mechanobiology describes the processes involved when mechanical cues from the changing physical microenvironment of the bone are transduced to biological pathways through mechanosensitive cellular components. Mechanobiology-driven therapies have been used to curb tumour progression by direct alteration of the physical microenvironment or inhibition of metastasis-associated mechanosensitive proteins. This review emphasizes the contribution of mechanobiology to the progression of osteosarcoma and sheds light on current mechanobiology-based therapies and potential new targets for improving disease management. Additionally, the many different 3D models currently used to study osteosarcoma mechanobiology are summarized.

Original languageEnglish (US)
Pages (from-to)201-217
Number of pages17
JournalBritish Journal of Pharmacology
Volume179
Issue number2
DOIs
StatePublished - Jan 2022

ASJC Scopus subject areas

  • Pharmacology

Fingerprint

Dive into the research topics of 'Osteosarcoma mechanobiology and therapeutic targets'. Together they form a unique fingerprint.

Cite this